Internal Standards (IS) monitoring in CROs: Anvisa perspective

A survey of regulatory recommendations for waivers of in vivo bioequivalence studies of generic products for certain dosage forms by participating regulators and organisations of the International Pharmaceutical Regulators Programme. Part 2.

Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques·2025

Chikungunya vaccine development, challenges, and pathway toward public health impact.

Vaccine·2024

Experiences and initiatives on pharmacokinetic modeling and simulation data analysis: Perspectives from the Brazilian Health Regulatory Agency (ANVISA).

Regulatory toxicology and pharmacology : RTP·2024

The bioequivalence study design recommendations for immediate-release solid oral dosage forms in the international pharmaceutical regulators programme participating regulators and organisations: differences and commonalities.

Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques·2024

Role of Physiologically Based Biopharmaceutics Modeling (PBBM) in Fed Bioequivalence Study Waivers: Regulatory Outlook, Case Studies and Future Perspectives.

Journal of pharmaceutical sciences·2023

The role of a genetically stable, novel oral type 2 poliovirus vaccine in the poliomyelitis endgame.

Revista panamericana de salud publica = Pan American journal of public health·2023

Development of a ready-to-use cell-based functional neutralizing antibody assay for MK-1484, a PEGylated IL-2 mutein that preferentially activates effector T-cells.

Bioanalysis·2026

STAT3 phosphorylation as an endpoint in a functional cell-based neutralizing antibody assay with potential for broad application.

Bioanalysis·2026

From anti-drug antibody incidence to clinical relevance: interpreting highly sensitive immunogenicity assays in biosimilars.

Bioanalysis·2026

Vaccine Ligand Binding Assay Development.

Bioanalysis·2026

From analytical similarity to clinical confidence: how regulatory evolution ensures comparable immunogenicity in streamlined biosimilar development.

Bioanalysis·2026

A DAR sensitive hybrid LBA-LC-MS/MS assay for quantitation of conjugated payload from a non-cleavable ADC in human serum.

Bioanalysis·2026

Sintilimab‑related cystitis/ureteritis in high‑grade endometrial stromal sarcoma: A case report and structured literature review.

Human vaccines & immunotherapeutics·2026

Multimodal discovery of a pathogenic B cell-dependent T cell state in multiple sclerosis.

Brain : a journal of neurology·2026

Phase I Evaluation of Siltartoxatug, a First-in-Class Anti-Tetanus Monoclonal Antibody: Safety, Pharmacokinetics and Pharmacodynamics in Healthy Australian and Chinese Populations.

Clinical pharmacology and therapeutics·2026

Thiolutin alleviates acute graft-versus-host disease (aGVHD) in a mouse model of allogeneic hematopoietic stem cell transplantation.

Blood science (Baltimore, Md.)·2026

Diagnostic Challenge of Immune Checkpoint Inhibitor-Induced Hypophysitis in Patient With Melanoma.

Federal practitioner : for the health care professionals of the VA, DoD, and PHS·2026

Thymic regeneration and tumor immunotherapy.

Frontiers in immunology·2026

Related Experiment Videos

Internal Standards (IS) monitoring in CROs: Anvisa perspective

Related Concept Videos

A survey of regulatory recommendations for waivers of in vivo bioequivalence studies of generic products for certain dosage forms by participating regulators and organisations of the International Pharmaceutical Regulators Programme. Part 2.

Chikungunya vaccine development, challenges, and pathway toward public health impact.

Experiences and initiatives on pharmacokinetic modeling and simulation data analysis: Perspectives from the Brazilian Health Regulatory Agency (ANVISA).

The bioequivalence study design recommendations for immediate-release solid oral dosage forms in the international pharmaceutical regulators programme participating regulators and organisations: differences and commonalities.

Role of Physiologically Based Biopharmaceutics Modeling (PBBM) in Fed Bioequivalence Study Waivers: Regulatory Outlook, Case Studies and Future Perspectives.

The role of a genetically stable, novel oral type 2 poliovirus vaccine in the poliomyelitis endgame.

Development of a ready-to-use cell-based functional neutralizing antibody assay for MK-1484, a PEGylated IL-2 mutein that preferentially activates effector T-cells.

STAT3 phosphorylation as an endpoint in a functional cell-based neutralizing antibody assay with potential for broad application.

From anti-drug antibody incidence to clinical relevance: interpreting highly sensitive immunogenicity assays in biosimilars.

Vaccine Ligand Binding Assay Development.

From analytical similarity to clinical confidence: how regulatory evolution ensures comparable immunogenicity in streamlined biosimilar development.

A DAR sensitive hybrid LBA-LC-MS/MS assay for quantitation of conjugated payload from a non-cleavable ADC in human serum.

Sintilimab‑related cystitis/ureteritis in high‑grade endometrial stromal sarcoma: A case report and structured literature review.

Multimodal discovery of a pathogenic B cell-dependent T cell state in multiple sclerosis.

Phase I Evaluation of Siltartoxatug, a First-in-Class Anti-Tetanus Monoclonal Antibody: Safety, Pharmacokinetics and Pharmacodynamics in Healthy Australian and Chinese Populations.

Thiolutin alleviates acute graft-versus-host disease (aGVHD) in a mouse model of allogeneic hematopoietic stem cell transplantation.

Diagnostic Challenge of Immune Checkpoint Inhibitor-Induced Hypophysitis in Patient With Melanoma.

Thymic regeneration and tumor immunotherapy.

Related Experiment Videos

Internal Standards (IS) monitoring in CROs: Anvisa perspective

Related Concept Videos

Related Articles